You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK)提名Kevin Patrick Lynch龍振國及為執行董事
格隆匯 05-28 22:14

格隆匯5月28日丨德琪醫藥-B(06996.HK)宣佈,劉翼騰及李甄鑑於集團下階段的戰略成長及彼等將投入更多時間於其他工作業務的計劃,已通知董事會彼等有意自董事會退任,且將不會尋求於股東周年大會上分別獲續任為執行董事及非執行董事。劉翼騰於股東周年大會上退任後,根據《上市規則》第3.05條,彼亦不再擔任公司的授權代表("授權代表"),自2021年6月18日起生效。

劉翼騰於股東周年大會上退任後將繼續擔任公司首席運營官。

同日宣佈,董事會有意提名Kevin Patrick Lynch博士及龍振國為董事會候任執行董事,將由股東於股東周年大會上審議及批准。董事會進一步宣佈,龍振國將獲委任為授權代表,自2021年6月18日起生效。

提名委員會已審查Kevin Patrick Lynch博士的資格、技能及經驗,認為Kevin Patrick Lynch博士為於多個國家及地區的臨牀開發及醫學事務擁有近30年經驗的專業人士,並建議董事會考慮建議委任彼為執行董事,以接替劉翼騰退任後的空缺。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account